Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2534.00, up by 0.70 points or 0.03% from its previous closing of Rs. 2533.30 on the BSE.

The scrip opened at Rs. 2521.60 and has touched a high and low of Rs. 2549.00 and Rs. 2498.25 respectively. So far 13461 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.

Last one week high and low of the scrip stood at Rs. 2725.00 and Rs. 2498.25 respectively. The current market cap of the company is Rs. 42043.41 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 44.50% and 14.44% respectively.

Dr. Reddy's Laboratories’ wholly owned subsidiary -- Aurigene Discovery Technologies (Aurigene) has entered into an exclusive collaboration, option and license agreement with Exelixis, Inc.

The agreement gives Exelixis the opportunity to in-license as many as six programs from Aurigene, which has developed a focused approach to drug discovery that targets differentiated first-in-class and best-in-class opportunities with unique mechanisms of action. The deal is part of Exelixis' ongoing strategy to build an innovative pipeline behind the company's internally discovered, commercially available therapies, including its flagship product, CABOMETYX (cabozantinib).

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.